瑞替普酶静脉溶栓治疗急性心肌梗死临床效果与安全性分析.docVIP

瑞替普酶静脉溶栓治疗急性心肌梗死临床效果与安全性分析 　　[摘要]目的 探讨分析瑞替普酶静脉溶栓在治疗急性心肌梗死（AMI）中的临床治疗效果与安全性。方法 选择在2012年7月―2014年6月期间，该院收治的全部符合标准的心肌梗死患者151例，按随机原则分为观察组75例和对照组76例，对照组患者使用药物尿激酶，而对于观察组患者，则给予瑞替普酶静脉溶栓，然后将两组患者的治疗效果进行对比和分析。结果 两组患者的冠状动脉再通率对比 观察组患者在静脉溶栓后0.5、1 h以及2 h冠状动脉的再通率分别33.5%、66%和88.5%，全部明显高于对照组，差异具有统计学意义（P0.05）；观察组和对照组患者在静脉溶栓以后4周内死亡率分别为4%和7.89%，该两组患者的死亡率对比，其差异没有统计学的意义（c2=0.267，P0.05）。结论 对于急性心肌梗死患者，使用药物瑞替普酶静脉溶栓，其冠状动脉的再通率高，酶峰值显著提前，而且安全可靠。 　　[关键词]尿激酶；瑞替普酶； 静脉溶栓；急性心肌梗死 　　[中图分类号]R969.4 [文献标识码]A [文章编号]1674-0742（2015）04（b）-0078-02 　　Analysis of the Clinical Effect and Safety of Intravenous Thrombolytic Therapy with Reteplase for Acute Myocardial Infarction 　　WEI Shuang 　　The Peoples Hospital of Jilin city of Huadian Province， Jilin 132400 China 　　[Abstract] Objective To investigate and analysis of reteplase in the treatment of acute myocardial infarction （AMI）clinical therapeutic effect and safety of. Methods To choose from July to 2014 during the period of 2012 June， our hospital all conform to the standards of the myocardial infarction in 151 patients， randomly divided into observation group 75 cases and control group 76 cases， control group with medication of patients with urokinase， and to observe patients， to give a reteplase thrombolytic therapy， and then the two groups patients were treated by comparison and analysis. Results The two groups of patients with coronary artery recanalization rate comparison in the observation group were intravenous thrombolysis after 0.5h，1h and 2h coronary artery recanalization rates were 33.5%，66% and 88.5%， are significantly higher than the control group， the difference has statistics significance （P0.05）； the observation group and the control group in the patients with intravenous thrombolytic therapy after 4 weeks of mortality were 4% and 7.89%， compared the mortality of the two groups， the difference was not statistically significance （c2=0.267， P0.05）. Conclusion For patients with acute myocardial infarction， the use of drugs of reteplase， cor